Chimeric antigen receptor T cell therapy: a ray of hope for refractory neurological autoimmune diseases
10.3760/cma.j.cn113694-20250115-00034
- VernacularTitle:嵌合抗原受体T细胞治疗：难治性神经系统自身免疫性疾病的曙光
- Author:
Chuan QIN
1
;
Daishi TIAN
1
;
Yuxin LIU
1
;
Wei WANG
1
Author Information
1. 华中科技大学同济医学院附属同济医院神经内科，武汉 430030
- Publication Type:Journal Article
- Keywords:
Neurological autoimmune diseases;
Chimeric antigen receptor T cell therapy;
Cellular therapy
- From:
Chinese Journal of Neurology
2025;58(4):341-346
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor (CAR) T (CAR-T) cell therapy has emerged as a promising treatment strategy for relapsed neurological autoimmune diseases (NADs). In response to this innovative approach, Chinese experts, combining clinical trial results and fully considering the actual medical needs in China, have developed the "Expert consensus on chimeric antigen receptor T cell therapy for neurological autoimmune diseases in China 2025". This consensus provides comprehensive guidelines on patients and cell product selection, treatment procedures, monitoring protocols, adverse event management, with the goal of standardizing clinical practice for CAR-T cell therapy in NADs. The consensus focuses on NADs, pays more attention to the actual situation of Chinese patients, and proposes implementation plans that are convenient for clinical practice, providing important guidance for the promotion of CAR-T cell therapy in the field of neurology in China.
